Showing 3031-3040 of 5646 results for "".
- Kaustabh Ghosh, PhD, Recognized With Catalyst Award for Innovative AMD Researchhttps://modernod.com/news/dr-kaustabh-ghosh-recognized-with-catalyst-award-for-innovative-amd-research/2481657/Doheny Eye Institute announced that Kaustabh Ghosh, PhD, was recently recognized by non-profits Research to Prevent Blindness (RPD) and the International Retinal Research Foundation (IRRF) with the Catalyst Award for innovative approaches for age-related macular degeneration (AMD). 
- Partnership Agreement Between Mireca and Graybug Terminatedhttps://modernod.com/news/partnership-agreement-between-mireca-and-graybug-terminated/2481631/Mireca Medicines announced that the partnership agreement between Mireca and Graybug (now CalciMedica) has been terminated due to a shift in drug development focus of CalciMedica away from ocular diseases. As part of the termination, all intellectual property rights that
- GenSight Biologics Withdraws its EMA Application for Lumevoqhttps://modernod.com/news/gensight-biologics-withdraws-its-ema-application-for-lumevoq/2481559/GenSight Biologics announced that it has decided to withdraw an application with the European Medicines Agency (EMA) seeking approval of Lumevoq (lenadogene nolparvovec) in patients with Leber hereditary optic neuropathy (LHON). The moves comes after the Committee for Advanced Therapies (CAT
- Ocutrx Technologies Acquires Circuit Board Manufacturing Company Spectrum Advanced Manufacturing Technologieshttps://modernod.com/news/ocutrx-technologies-acquires-circuit-board-manufacturing-company-spectrum-advanced-manufacturing-technologies/2481531/Ocutrx Technologies announced it has acquired Spectrum Advanced Manufacturing Technologies, a Colorado-based electronics manufacturing and assembly company. Terms of the deal were not disclosed. With this acquisition, the consolidated Oxutrx_Spectrum company now
- Lumata Health and Prevent Blindness Announce Partnership Aimed at Delivering More Resources to Americans with Vision Losshttps://modernod.com/news/lumata-health-and-prevent-blindness-announce-partnership-aimed-at-delivering-more-resources-to-americans-with-vision-loss/2481522/Lumata Health announced a partnership with Prevent Blindness which will focus on various initiatives to address barriers to care for patients, with a strong focus on mental health resources to start. “Our care coordinators are in frequent contact with pati
- EverSight Launches Preloaded DMEK EndoGlidehttps://modernod.com/news/eversight-launches-preloaded-dmek-endoglide-1/2481517/Nonprofit eye bank Eversight announced the availability of Descemet’s membrane endothelial keratoplasty (DMEK) tissue preloaded in EndoGlide, offering corneal surgeons a fourth preloaded DMEK option to further s
- American Academy of Optometry Foundation Now Accepting Applications for 2023 Residency Awardshttps://modernod.com/news/american-academy-of-optometry-foundation-now-accepting-applications-for-2023-residency-awards/2481516/The American Academy of Optometry Foundation is accepting requests for applications for its 2023 Residency Awards. Applications must be received by Tuesday, June 1, 2023. Award opportunities include: Douglas Hopkins Primary Care Eye Residency Award&nb
- CDC: Cases of Vision Loss and Death Due to Drug-Resistant Bacteria Linked to Artificial Tears Continues to Risehttps://modernod.com/news/cdc-cases-of-vision-loss-and-death-due-to-drug-resistant-bacteria-linked-to-artificial-tears-continues-to-rise/2481488/Federal officials say three people have died as part of a growing number of cases of infections from a rare, extensively drug-resistant strain of Pseudomonas aeruginosa found in some artificial tears. There have also been 8 reports of vision loss and 4 reports of enucleatio
- Aurion Biotech Receives Approval in Japan for First Allogeneic Cell Therapy to Treat Corneal Endothelial Diseasehttps://modernod.com/news/aurion-biotech-receives-approval-in-japan-for-first-allogeneic-cell-therapy-to-treat-corneal-endothelial-disease/2481486/Aurion Biotech announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its novel cell therapy, Vyznova, for the treatment of bullous keratopathy of the cornea. The company believes this is the first regulatory approval in the world fo
- OcuSciences Announces Publication Showing Potential to Detect Retinal Diseases with High Sensitivityhttps://modernod.com/news/ocusciences-announces-publication-showing-potential-to-detect-retinal-diseases-with-high-sensitivity/2481484/OcuSciences announced a publication in